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Endothelium regulates vascular homeostasis, including coagulation and perme-
ability, bymodulating theexpression of cell surfacemolecules and secreted products
in response to blood-borne mediators and those emanatingfrom the vessel wall . Re-
cent studies have emphasized the responses of endothelium to cytokines, such as
TNF/cachectin and IL-1, which perturb a range of homeostatic endothelial func-
tions (20, 46, 48).
The progressive accumulation of irreversible advanced glycosylation end prod-
ucts (AGE)' (8, 10, 11) on both plasma and subendothelial tissues, such as vascular
basement membrane proteins, may constitute a potentially significant perturbant
of endothelial cell function . Recent studies have focussed on these biologically im-
portant covalent products ofthe nonenzymatic glycosylation reaction, which derive
slowly from the early Amadori product after a sequence of further reactions and
rearrangements (8, 10, 11, 33) . Theseadducts are characteristically fluorescent, yellow-
brown pigments that can crosslink proteins and nucleic acids (8) . Accumulation of
AGES on long-lived proteins in vivo has been found to increase linearly with age
(33), is accelerated in patients with diabetes, and is thought to be an important con-
tributor to the development ofa host of complications, such as vascular and renal
disease (11) . The identification and isolation of a receptor on human and murine
macrophages that selectively recognizes AGE adducts on proteins (41) support the
concept that these modified macromolecules may exert specific effects on tissue or
cellular targets (50, 51, 53) . In this context, interaction ofAGE-BSA with macro-
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phages has been shown to induce the elaboration ofTNF/cachectin and IL-1, thereby
initiating a sequence of events by which macrophages remove and orchestrate the
replacement ofsenescent proteins (54). Under pathologic conditions, such as in dia-
betes or atherosclerosis, AGEs may contribute to the pathogenesis of proliferative
vascular lesions (10).
These considerations, and the fact that endothelium is in direct contact with suben-
dothelial, as well as circulating AGEs, led us to examine the interaction ofendothelium
with AGE-BSA, as a prototype of this class of nonenzymatically glycosylated pro-
teins. The results indicate that AGE-BSA binds in a saturable manner to the cell
surface with subsequent uptake by endocytosis, which leads to either transcytosis
or eventual transfer to a lysosomal compartment. Functional consequences ofAGE-
BSA-endothelial interaction include increasing permeability of the monolayer and
alteration ofcell surface coagulant properties, potentially promoting clot formation.
These data indicate that AGE derivatives of proteins, ubiquitous components of the
vascular milieu in diabetes (11, 33) and also in normal aging (29), interact directly
with the endothelium, potentially contributing to the pathogenesis of subsequent
vascular dysfunction.
Materials and Methods
Cell Culture.
￿
Bovine aortic endothelial cells were grown from aortas of newborn calves
in MEM supplemented with penicillin-streptomycin (50 U/ml, 5 hg/ml), glutamine, and FCS
(10%) as described (6, 44). Cultures were characterized as endothelial based on morphologic
criteria, immunofluorescence for protein S, von Willebrand factor, and thrombomodulin (17,
25, 47). Cells were separated for subculture with trypsin/EDTA. For experiments, cells from
different aortas were grown to confluence in 9.6-, 2-, or 0.32-cm2 wells (1.1-1.5 x 105
cells/cm2) and used from passages 3-16, within 48 h of having achieved confluence. For per-
meability studies, cultures were grown as described previously (7) on 6.5-mm diameter poly-
carbonate membranes (pore size 0.4 Am), mounted on polystyrene inserts (Transwell plates;
Costar, Cambridge, MA), and used for studies 10 d after plating.
Preparation and Radiolabeling ofAGE-BSA.
￿
AGE-BSA was prepared by incubating BSA (frac-
tion V; Boehringer-Mannheim Biochemicals, Indianapolis, IN) in 10 mM PBS buffer, pH
7.4, with 50 mM glucose at 37°C for 6 wk in the presence of protease inhibitors (1 .5 mM
PMSF and 0.5 mM EDTA) and antibiotics (100 U/ml penicillin and 40 pg/ml gentamicin)
as described previously (41). The amount of AGE formed on all BSA preparations was as-
sessed by characteristic absorption and fluorescence spectra (29) and quantitated by RIA
using 2-furoyl-4-(5)-(2-furanyl)-1H-imidazole (FFI, a chemically synthesized AGE) (12, 39),
which has been shown to be recognized by the macrophage AGE receptor (51-53), as a stan-
dard. According to this assay, our routinely prepared AGE-BSA conjugates have +360 pmol
FFI equivalents/mg BSA. SDS-PAGE showed a single major band with M, "67,000 (data
not shown). Radiolabeling was accomplished by the lactoperoxidase method (15) using En-
zymobeads (Bio-Rad Laboratories, Sacramento, CA) by incubating AGE-BSA (50 ug) with
50 pl of beads for 3 min at 4°C. The reaction was stopped by the addition of azide, beads
were pelleted by centrifugation, and free iodine was removed by gel filtration on a Sephadex
G-25 column pre-equilibrated with MEM containing 1% FCS. The specific radioactivity
of the tracer was 1.5 x 103 cpm/ng over four iodinations and autoradiograms prepared from
SDS-polyacrylamide gels (30) (10% ; nonreduced) demonstrated a single band corresponding
to Mr -67,000. Nonglycosylated albumin, used for controls, was prepared in an identical
fashion except that glucose and glucose 6-phosphate were omitted from the incubation buffer.
Murine ribonuclease and hemoglobin (Sigma Chemical Co., St. Louis, MO) were glycosylated
and characterized as described for AGE-BSA (51, 53 54).
Preparations ofAGE-BSA used for specific experiments were prepared under endotoxin-
free conditions, and passed over an affinity PAK column (Detoxigel; Pierce Chemical Co.,ESPOSITO ET AL.
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Rockford, IL). All solutions were assessed for contaminating endotoxin by a standard Limulus
amoebocyte assay (Sigma Chemical Co.) and found to be negative (54). In some experiments
polymyxin B (100 ng to 10 hg/ml) was added to determine whether any responses reflected
trace amounts of LPS undetectable by Limulus assay.
Binding and Internalization Studies.
￿
The binding of 1251-AGE-BSA to endothelial cell
monolayers was studied after washing cells four times in a balanced salt solution (10 MM
Hepes, pH 7.45, 137 mM NaCl, 4 mM KCI, 11 mM glucose) over 15 min and the addition
of MEM containing 5 % FCS. Radiolabeled AGE-BSA alone or in the presence ofa 100-fold
molar excess of unlabeled material, each in a volume of 5 1 .1, was then incubated with the
cells for the indicated times at VC. Where indicated, other competitors were added to the
incubation mixture. Binding was terminated by 10 rapid washes (over _30 s) with MEM
containing 1% FCS, and bound material was then eluted by exposing the cultures to buffer
containing EDTA (5 mM), heparin (10 mg/ml), and BSA (1 mg/ml) in a balanced salt solu-
tion for 5 min at 37oC. Where indicated, cells were eluted by incubation with NP-40 (1%)
for 5 min at 37°C. Specific binding was defined as the difference ofbinding observed in wells
incubated with 1251-AGE-BSA alone and binding observed in wells incubated with 1251-AGE-
BSA in the presence of a 100-fold molar excess ofunlabeled AGE-BSA (51). No specific binding
was observed in wells without cells. Data from binding experiments were fit to the equilib-
rium binding equation B = nKA/(1 + KA), where B is the amount of specifically bound
ligand, n is the number of binding sites per cell, A is the concentration of free radioligand,
and Kis the association constant (28). A nonlinear least-squares program was used to obtain
the best fit curve, to solve for n and K, and to determine the standard error.
Dissociation studies used the method of infinite dilution (31); after binding of ligand to
the cell surface, cultures were washed 10 times and then fresh MEM with FCS was added.
At the indicated times, wells were washed again and bound radioactivity was determined.
In pilotstudies, similar results were observed using either this method or by studying dissoci-
ation in the presence of excess unlabeled ligand.
Endocytosis experiments were performed at 37°C as described previously (37) by incubating
the cells with 1251-AGE-BSA alone or in the presence of excess unlabeled material. Cell-
associated radioligand wasdivided into two pools: surface-bound material, eluted with heparin
(10 mg/ml)/EDTA (5 mM)-containing buffer (5 min at 37'C), and internalized material,
eluted aftersolubilizing the cells in buffer containing NP40 (1% ; 5 min at 37'C). Degraded
radioligand present in the culture supernatant was assessed by serial precipitation ofaliquots
of culture medium in trichloroacetic acid (5%) during the incubation period.
Assessment ofEndothelialMonolayerPermeabilityafterExposuretoAGE-BSA.
￿
Confluent endothelial
monolayers plated on Transwell inserts (see above) were washed with Earle's balanced salt
solution and MEM containing FCS (5%) and either AGE-BSA, heat-treated AGE-BSA (10
min at 90°C), ornormal BSA was added for the indicated times. At the end ofthis incubation
period, permeability of the endothelial monolayer was assessed by studying the passage of
[3H]inulin (271 mCi/p,g; New England Nuclear, Boston, MA) across the membranes as de-
scribed previously (7, 16, 45). In brief, fresh medium was added to both the inner and outer
(corresponding to upper and lower) chambers such that the oncotic and hydrostatic pressures
in the two chambers were equal. A radiolabeled marker, [3H]inulin, was then added in trace
amounts (_3 pg/ml) to the upper chamber. Transfer of tracer across the monolayer was as-
sessed by serial sampling ofthe lower chamber (the volume in the chambers was not changed
significantly, <5%, as a result ofsampling) and was expressed as the quotient of radioactivity
emerging in the outer well divided by radioactivity remaining in the inner well.
Assessment ofEndothelial Coagulant Properties after Exposure to AGE-BSA..
￿
Cultures were in-
cubated with AGE-BSA in MEM containing 5% FCS and polymyxin B (1 fig/ml) for the
indicated times at 37°C and cell surface thrombomodulin and tissue factor were assessed.
Where indicated, nonglycosylated BSA or heat-treated AGE-BSA (10 min at 90°C) replaced
AGE-BSA. Purified recombinant human TNFa (_108 U/mg, generously provided by
Hoffman-LaRoche, Nutley, NJ) was also added to the cultures in certain experiments. For
thrombomodulin functional assays (38), cultures were washed four times in balanced salt
solution and then incubated for 15 min at 37°C in 10 mM Hepes, pH 7 .45, 137 mM NaCl,
11 mM glucose, 4 mM KCI, 2 mM CaC12, and 2 mg/ml BSA containing protein C (1001390
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lAg/ml) and thrombin (0.1 U/ml). Formation of activated protein C was terminated by the
addition of antithrombin III (100 wg/ml) and the amount ofenzyme formed was determined
using a chromogenic assay, hydrolysis of the substrate Lys-Pro-Arg-p-nitroanilide (Spectro-
zyme; American Diagnostica, New York, NY). Enzyme concentration was determined by
comparison with a standard curve made in the presence ofknown amounts of activated pro-
tein C. Thrombomodulin antigen was determined by a RIA with a monospecific polyclonal
antibovine thromobomodulin antibody. This antibody was produced in rabbits by standard
methods (22). RIA was carried out by a modification of the procedure described for human
factor IX (49). In brief, the assay was performed in 1.5-ml microcentrifuge tubes by adding
1251-thrombomodulin (5 pl), antithrombomodulin antiserum (10 td), and incubation buffer
(20 Wl; Tris, 20 mM, pH 7.4, NaCl, 0.1 M, and NP-40, 1%). Selected tubes contained either
samples or thromobomodulin standard diluted in the assay buffer (20 JAI). All dilutions were
made with incubation buffer. Tubes were incubated overnight at 4°C after which 50 tl of
a 10% suspension of Staphylococcus protein A (IgGSorb; Enzyme Center, Inc., Walden, MA)
was added to each tube for 30 min at 21°C . Incubation buffer (500 pl) was added next, and
the tubes were centrifuged for 3 min at 13,000 rpm. The supernatant was aspirated and dis-
carded, the bottom ofeach tube containing the pellet was cut off with a hot wire, and counted.
Bovine thrombomodulin was purified from lungs by the method ofJakubowski et al. (26)
and radiolabeling of preparations was carried out by the lactoperoxidase procedure (15), as
described above for 1251-AGE-BSA. The sensitivity of this assay was 10 ng/ml, which cor-
responded to 80 % binding on the standard curve. The thrombomodulin content ofuntreated
endothelial cultures was -40-60 ng/106 cells.
Tissue factor activity ofendothelial cell monolayers was determined using a coagulant assay
after detaching cells from the growth surface by scraping. In brief, after washing monolayers,
cells were scraped with a rubber policeman and suspended in barbital-buffered saline. A two-
stage coagulant assay was then carried out as described previously (36). Where indicated,
cells were preincubated with a mAb to bovine tissue factor at 10 wg/ml for 30 min at 37°C
(this antibody was generously provided by Dr. R. Bach, Mt. Sinai Medical Center, New York,
NY). Quantification of tissue factor was accomplished by comparing clotting times with a
standard curve generated with known amounts ofpurified tissue factor (2). In certain experi-
ments, endothelium was incubated with AGE-BSA in the presence of the indicated concen-
tration of TNF.
Microscopy.
￿
AGE-BSA colloidal gold conjugates were prepared and used by the general
method described previously (37). In brief, suspensions of colloidal gold were prepared (18)
with an average diameter of 12 nm (1) and conjugated to albumin at pH 6.0. Complete sur-
face labeling was achieved, as determined by the serial electrolyte test (24) and labeled col-
loids were evaluated for stability as previously described (21). Experiments with gold-labeled
AGE-BSA were carried out according to the same general protocols outlined above for radio-
labeled AGE-BSA. After binding of gold particles to the surface, unbound particles were re-
moved by washing and samples were prepared for electron microscopy; samples were fixed
in 2.5% glutaraldehyde in 0.1 M cacodylate buffer for 30 min, postfixed in 2°Jo osmium
tetroxide, dehydrated in ethanol, and embedded in EPON. Sections were viewed in a Phillips
300 electron microscope.
The effects of AGE-BSA on the endothelial actin-based cytoskeleton and cell shape were
assessed by fluorescence microscopy, using rhodamine phalloidin staining to display F-actin.
These methodshave been described previously (7). Indirect immunofluroescence for throm-
bomodulin was carried out by procedures described previously (37, 47).
Results
Binding of Cellular Processing ofAGE-BSA by Endothelium.
￿
At 4°C, specific binding
of 1251-AGE-BSA to cultured bovine aortic endothelial cells (the difference between
binding of 1251-AGE-BSA to endothelium incubated with tracer alone and binding
in the presence of excess unlabelled ligand) was observed when cell-bound material
was eluted with a buffer containing NP-40 (1%) (Fig. 1 A). Since detergent-treat-
ment of cell monolayers removes both cell surface and internalized ligand, a methodESPOSITO ET AL .
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FIGURE 1 .
￿
Bindingof I25I-AGE-
BSA to endothelial cell monolayers :
methods of elution . Binding was
studiedat 4°C (A)and at 37°C (B) .
Endothelium was incubated with
1251-AGE-BSA (100 nM) alone
(open bars) or in the presence of a
100-fold molar excess ofunlabeled
AGE-BSA (shadedbars) for4hat the
indicated temperature. Cultures
were then washed 10 times and
eluted with one of the following
agents : heparin-heparin (10 mg/
ml)/EDTA (5 mM); NP-40 = I%
NP-40. Data shown in A-B are a percent of total '251-AGE-BSA binding elutable with NP-40 when
the binding experiment was carried out at 37°C . (C) Cultures were incubated for 4 h at 37°C with
I251-AGE-BSA (80 nM) alone or in the presence ofunlabeledAGE-BSA (10 pM), washed 10 timesand
eluted first with heparin/EDTA as above and then with NP-40 . Thedata shown represent specifically
cell-bound 125I-AGE-BSA (the difference of radioligand eluted from cultures incubated with tracer alone
and radioligand eluted from cultures incubated with tracer in the presence of unlabeled AGE-BSA)
after sequential elution : first with heparin/EDTA (heparin) and then with NP-40 . The mean t SD
is shown in each case .
for selective elution ofcell surface-bound material was developed . Based on reports
that heparin could prevent the binding ofAGE-BSA to murine peritoneal macro-
phages (52), abuffer containing heparin (10 mg/ml)/EDTA (5 mM)was used to elute
cell-associated I25I-AGE-BSA. Specifically bound 1251-AGE-BSA eluted in the pres-
ence ofheparin/EDTA was the same as that observed after elution with detergent
at 4°C (Fig . 1 A), and probably represented selective elution from the cell surface.
Studies in which endothelium with bound 125I-AGE-BSA was exposed to trypsin
(5 wg/ml for 5 min at 21 °C) confirmed that elution withheparin/EDTA represented
complete removal of specifically bound cell surface material (data not shown). At
37 °C, endocytosis ofAGE-BSAoccurred and in addition to the surface-bound ma-
terial observed at 4°C, an internalized pool formed (see below, 37°C studies, and
Fig . 1 B-C) .
To complement the radioligand binding experiments, interaction of AGE-BSA
colloidal gold conjugates with endotheliumwas studied at 4°C. Incubation ofAGE-
BSA-gold particles with endothelium resulted in binding ofgold particles to the cell
surface which could be eluted by brief exposure to heparin/EDTA (Fig . 2, A-B) .
Furthermore, a 100-fold molarexcess ofAGE-BSA not boundto gold particlesblocked
binding ofAGE-BSA colloidal gold conjugates by >95% . Since these studies were
carriedout in thepresence ofFCS (5%), which contains BSA but notAGE adducts
ofproteins (data not shown), theobserved bindingdoes not represent BSA-endothelial
cell interaction . Furthermore, identicalbindingwasobserved in the presence of excess
normal albumin(I% ; data notshown) . These results suggested that radioligand binding
studies at 4°C could be done to assess parameters of 115I-AGE-BSA binding to en-
dothelial cell surface .
Binding of"'I-AGE-BSA to endothelium at 4°C was time dependent, reaching
an apparent maximum by 3 h, even at the lowest concentrations oftracer used (Fig .
3 A) . The apparent second order rate constant for association, calculated from the
data in Fig . 3 A, was -0.13 x 10'/M/min . The concentration of binding sites used
in this calculation was taken from the data in Fig . 3 C. Dissociation studies (Fig .1392
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FIGURE 2 .
￿
Binding of AGE-BSA-colloidal gold conjugates to endothelial monolayers . (A-B).
Endothelial cell monolayers were incubated at 4°Cwith AGE-BSA-gold (100 nM) for 2 h, washed,
and then either fixed for electron microscopy (A) or eluted with heparin (10 wg/ml)/EDTA
(5 mM)and then prepared for electron microscopy (B) . (C-D) Monolayers were incubated with
AGE-BSA-gold (100 nM) for2 h at 4°C, washed, further incubated at 37°C for 2 h (C) or 20 h
(D), and then prepared for electron microscopy . After the 4°C incubation, AGE-BSA-colloidal
gold particles were bound to the cell surface (A) . Cells treated withheparin/EDTA did not display
gold particles on the cell surface (B) . After 2 h at 37°C, AGE-BSA gold particles were primarily
associated with multivesicular bodies within the cytoplasmandbound to subcellular matrix com-
ponents (C) . By 20 h at 37°C, large accumulations of AGE-BSA gold particles were found in
association with the extracellular matrix (D) . Bar, 0.1 Am .
3 B) indicated that the interaction of 12'1-AGE-BSA with endothelium was revers-
ible with an apparent first-order dissociation constant of-0.07/min . Although -90
min was required for complete dissociation, during this time cell-associated AGE-
BSA remained on the cell surface, since a 3-min exposure to buffer containing
heparin/EDTA resulted in rapid elution of bound 1251-AGE-BSA, but did not dis-
rupt the intact monolayer . SDS-PAGE of cell-bound radioligand eluted with hepa-20
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FIGURE 3.
￿
Bindingof 125I-AGE-BSAto endothelial cell monolayers at 4°C. (A)Time course.
Monolayers were incubated with 121I-AGE-BSA (1, 25 nM; 2, 10 nM; 3, 1 nM)alone or in the
presence ofa 100-fold molarexcess of unlabeledAGE-BSAfortheindicatedtimes. Cultures were
then washed 10 times and eluted with heparin/EDTA as described in the text. Specific binding,
total binding (observed in the presence of 1251-AGE-BSA alone) minus nonspecific binding(ob-
served in thepresence of 1251-AGE-BSAandexcess unlabeledligand) is shown (the mean ofdupli-
cates). Low concentrations of radioligand were used in this studyto allowdeterminationofincu-
bation times necessary to achieve apparent maximal binding with these amounts of
1251-
AGE-BSA (this information was necessary to carry out theexperiment in C). (B) Reversibility.
Monolayers were incubated with 1251-AGE-BSA (100 nM) alone (total binding) or in the pres-
ence of a 100-fold molarexcess of unlabeled AGE-BSA(nonspecific binding) for4 handwashed
10 times. At this point (time 0), cultures were incubated for the indicated additional times at
4°C. Cultures were then washed andeluted withheparin/EDTA-containing buffer. Maximal specific
binding(time0) was85 fmol perwell. Theaverage ofduplicatedeterminations ofspecific binding
is shown as a percent of maximal specific binding and is plotted versus time. (C) Saturability
of binding. Endothelial cell monolayers were incubated with theindicated concentrations
1251-
AGE-BSA alone or in the presence of a 100-fold molar excess of unlabeled AGE-BSA for 4 h
at 4°C. Cultures were then washed and eluted with heparin/EDTA. Specific binding versus the
concentration of free tracer is plotted. Data were analyzed by the nonlinearleast squares pro-
gram and the curve indicates the best fit line. (D) Competitive binding studies. Endothelial
monolayers were incubated with 1251-AGE-BSA (100 nM) alone or in the presence of the indi-
cated concentration of either unlabeled AGE-BSA (circles) or normal BSA (diamonds) for4 h at
4°C. Maximal binding(90 fmol/well) was defined as theamount of 125I-AGE-BSAboundwhen
1251-AGE-BSA was incubated with cultures alone minus the amount of 1251-AGE-BSA bound
in thepresence ofa 100-fold molarexcess ofunlabeledAGE-BSA. Theaverage ofduplicatedeter-
minations is shown. Details of experimental procedure are described in the text.1394
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rin/EDTA demonstrated a single band that migrated identically to the initial tracer
with M r -67,000 (datanot shown). This indicates that cell surface-bound 1251-AGE-
BSAhasnotformed covalent complexeswith cellular proteins andhas not been cleaved
during or as a consequence of binding, based on comparison with the initial tracer
by electrophoretic analysis.
Using these conditions for equilibrium binding, the association of 1251-AGE-BSA
with endothelium was found to be saturable (Fig. 3 C). Binding was half-maximal
at 99 t 18 nM, and at saturation there were 2.6 t 0.3 x 106 molecules bound/cell.
Experiments in which 1251-AGE-BSA was diluted with unlabeled AGE-BSA showed
comparable binding parameters, indicating that unlabeled and labeled AGE-BSA
interacted with endothelium similarly. Consistent with this interpretation, unlabeled
AGE-BSA was an effective competitor for 1251-AGE-BSA-endothelial cell binding,
whereas unmodified BSA was not (Fig. 3 D). These results suggested that the cell
surface binding sites for AGE-BSAwere specific forthe AGE adduct ofthe protein.
This led us to examine if AGE adducts of other proteins could compete with
1251-AGE-BSA foroccupancy ofthe binding sites (Fig. 4). Although nonglycosylated
ribonuclease and hemoglobin failed to inhibit the binding of 12'I-AGE-BSA to en-
dothelium, theAGE-modified forms ofthese proteins were competitors. Furtherevi-
denceemphasizing the importance of AGE moieties for interaction with the cellular
receptor is derived from experiments indicating that neither addition of glucose (at
a concentration of 45 or 90 mM) nor albumin incubated with glucose or glucose
6-phosphate for 1, 3, or 6 d, at which time little, if any, AGE is present (29), in-
hibited binding of 12'I-AGE-BSA to endothelium (Fig. 4). However, after incuba-
tion of albumin with glucose or glucose 6-phosphate for 16 d or more, which results
in sufficient AGE adduct formation (9), this modified form of the protein became
a competitor of 12'I-AGE-BSA binding to the cell surface. These results suggested
that the cell surface binding site recognizes the AGE-modified derivatives of a va-
rietyofproteins and ledus to examinesubsequent processing ofsurfacebound ligand.
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FIGURE 4. The effect of AGE-
ribonuclease, AGE-hemoglobin,
and glucose on the binding of1251_
AGE-BSA to endothelium. Endo-
thelial monolayers were incubated
for 4 h at 4°C with 1251-AGE-BSA
alone (100 nM; first bar) (0) or in
the presence ofoneofthe following
unlabeled competitors: AGE-BSA
(10 AM), AGE-ribonuclease (10
AM), ribonuclease (10 AM), AGE-
hemoglobin (10 AM), hemoglobin
(10-ÁM), or BSA (albumin) incu-
bated with glucose forthe indicated
number of days (each at a concen-
tration of20 AM). Where indicated
8
￿
(glucose), the incubation medium
for cell binding studies was sup-
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plemented with additional glucose,
either 4,5 or 90 mM. Data shown,
the average ofduplicate determina-
tions, are expressed as percent max-
imal binding of 1251-AGE-BSA.Several pieces of evidence indicated that at 37 °C, binding of 1251-AGE-BSA to
the cell surface was followed by entry into an intracellular compartment, presum-
ably by endocytosis. First, in contrast to the complete elution of radiolabeled AGE-
BSA specifically associated with endotheliumby heparin/EDTA at 4°C, at thehigher
temperature sequential treatment of cultures with heparin/EDTA followed by NP-
40 demonstrated an additional pool of cell-associated 1251-AGE-BSA only elutable
with detergent (Fig. 1, B-C). Second, dissociation studiesdemonstrated only incom-
plete dissociation of 1251-AGE-BSA at 37°C. Residual bound ligand was not acces-
sible on the cell surface; briefexposure of cultures to trypsin, whichremoves surface-
bound 1251-AGE-BSA (see above), only achieved partial elution at 37°C. Taken
together, these data pointed to the formation of an intracellular pool of 1251-AGE-
BSA at 37 °C, which followed interaction of the ligand with a limited number of
receptors since thepresence of excess unlabeled AGE-BSA prevented its appearance.
Based on these results, further studies with 1251-AGE-BSA were performed to
characterize the nature ofcellular processing of theligand at 37'C. Fortheseexperi-
ments, cell-associated 1251-AGE-BSA was divided into two pools; surface-bound
radioligand, eluted by brief (3 min) exposure of the cells to buffer containing
heparin/EDTA, and internalized 1251-AGE-BSA, eluted by detergent solubilization
of monolayers with NP-40 (1%) after surface-bound material had been removed.
At 37°C, 1251-AGE-BSA (160 nM) was bound to the cell surface, reaching a max-
imum by about 4 h andwas also in an internalized pool. Formation of the internal-
ized pool correlated with evidence of endocytosed ligand based on visualization of
AGE-BSA colloidal gold conjugates (see below and Fig. 2, C-D). In addition,
1251-AGE-BSA in culture supernatants at 37°C was apparently becoming degraded,
evidenced by decreasedprecipitation ofradiolabeled material in trichloroacetic acid
(Fig. 5). Appearance ofdegraded material in culture supernatants could be prevented
by the addition of excess unlabeled AGE-BSA, indicating that uptake of the ligand
occurred by a limited number o£ cell surface binding sites. Taken together, these
data indicate that endocytosis ofAGE-BSAwith subsequent lysosomal-mediated degra-
dation is one pathway by which intracellular processing occurs. However, degrada-
tion could also be occurring in othercompartments, such as at the basal cell surface
aftertranscytosis. Studieswith chloroquine, an inhibitorofintracellularacidification
ESPOSITO ET AL.
￿
1395
FIGURE 5. Binding and cellular processing of 125I-
AGE-BSA by endothelial cell monolayers at 37°C. En-
dothelial cell monolayers were incubated with 125I-
AGE-BSA(160 nM)fortheindicated timesat 370C. The
amount ofsurface-bound(heparin/EDTA elutable)(tri-
angle), internalized (diamond; NP-40elutable after pre-
viousheparin/EDTA elution), anddegraded (circle; ma-
terial in culture supernatants which remained in the
soluble phase after precipitation ofproteins in trichlo-
roacetic acid)ligand wasdetermined as describedin the
text. Each point is the average of duplicate wells.1396
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that blocks degradationofavariety ofinternalized ligands(13) were carried out next
to provide additional supportfor amechanismofAGE-BSAprocessing by alysosomal-
dependent mechanism. The results were inconclusive, however, since this agent al-
tered AGE-BSA bindingto the cell surface and thus perturbed formation of the in-
tracellular pool of ligand. Thus, although the radioligand and morphologic studies
both support a role for intracellular degradation of AGE-BSA, ligand may also be
degraded in other locations after receptor-dependent uptake by the cells, such as
the subendothelial space.
Ultrastructuralstudiesalso indicatedthat entocytosis was occurringat 37°C (Fig.
2, C-D). AGE-BSAcolloidal gold conjugates boundto the cell surfacewere internal-
ized with transfer of ligand to a vesicular compartment. This was followed by ac-
cumulation ofAGE-BSA gold particles in multivesicular bodies, lysosomal-like struc-
tures, and/or transfer ofgold particlesthrough the cell with deposition on thesubcellular
matrix. After 2 h at 37°C, AGE-BSA gold particles had accumulated primarily in
multivesticular bodies although small clusters andindividual particleswere associated
with components of the extracellular matrix (Fig. 2 C). By 20 h, large aggregates
ofAGE-BSA gold particleswere associated with matrix components. AGE-BSA gold
particles were never observed within intercellularjunctions. Unlabeled AGE-BSA
could block cellular processing of AGE-BSA gold particles, presumably by blocking
its bindingto the cell surface. In addition, gold particles conjugated to native BSA
did not demonstrate similar intracellular uptake and deposition in the matrix (data
not shown).
Modulation ofEndothelial Cell Barrier Function by AGE-BSA.
￿
In view of the associa-
tion of advanced glycosylation endproducts with vascular complications, in which
increased vascular permeability is often evident, especially in diabetes, peturbation
of endothelial barrier function by AGE-BSA was assessed (Fig. 6). Confluent en-
FIGURE 6.
￿
Effect ofAGE-BSAon the
permeability ofendothelial monolayers.
(A) Endothelial monolayers on filters
were incubated in I% FCS alone (III)
or supplemented with AGE-BSA(250
nM; II) for 48 h and then transfer of
[3H]inulin across the monolayerover
4hwasassessed asdescribedin thetext.
Passage of [3H]inulin across a filter
without cells is shown (1). (B) Time
course. Endothelial monolayers on
filterswere incubatedin growth medi-
um containing 1% FCS supplemented
with AGE-BSA(500 nM)forthe indi-
cated times. Then, cultures were
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dothelialmonolayers on filters form abarrierrestricting thepassage of macromolecules
and lower molecular weight solutes (Fig. 6 A) (7, 16, 45). Using this experimental
system, cultures incubated with AGE-BSA demonstrated an increase in their per-
meability; after a48-h incubation with AGE-BSA(250 nM) therewas atime-dependent
increase in the passage of the inert macromolecular tracer [3H]inulin evident by 3
h (Fig. 6 A). Perturbation of endothelial barrier function depended on the amount
of time cultures were exposed to AGE-BSA, requiring -24 h to be significantly in-
creased above the baseline (Fig. 6 B). Increased permeability of monolayers in re-
sponse to AGE-BSA was reversible, with barrier function being restored by 72 h
after removal of AGE-BSA and addition of fresh medium (data not shown). The
effect of AGE-BSA on permeability was also dose dependent, being half-maximal
at 100-300nM over several experiments, whichapproximately corresponds to AGE-
BSA concentrations resultingin half-maximal occupancy ofthecell surfacebinding
sites. In contrast, addition of excess normal BSA (in addition to that present in the
serum-containing medium present in the incubation mixture) had no effect on
monolayerpermeability. These data suggest that AGE-BSA-induced increase in en-
dothelial permeability is a consequence of AGE-BSA interaction with the cell sur-
face receptor.
Since endotoxin can also modulate endothelial permeability (23), and this agent
could potentially be present as acontaminant in theAGE-BSApreparations, studies
were carried to exclude this possibility (Fig. 6 B). Heat treatment of AGE-BSA
prevented its effect on endothelial permeability underconditions that we have previ-
ously foundnotto affect endotoxin-induced alterations in arangeofendothelial func-
tions (38; data not shown) . In addition, the LPS content ofAGE-BSA preparations
was found to be negative, as monitored by a standard limulus amoebocyte assay,
and in the presence of polymyxin B (3).
Concomitant with AGE-BSA-induced perturbation of monolayer barrier func-
tion, therewas an alteration in cell shape/cytoskeletal organization (Fig. 7). Confluent
endothelial cultures form a contiguous monolayer with actin-based cytoskeletons
characterized by variable central stress fiber arrays and prominent circumferential
stress fiber bundles (Fig. 7 A). After exposure to AGE-BSA at 10 nM for 48 h, a
dose that resultsin minimalalteration ofbarrierfunction, cellswere contiguous and
tightly apposed, but both peripheral and central stress fiber arrays were reduced,
and punctate actin foci appeared in the perinuclear cytoplasm (Fig. 7 B). At ahigher
dose of AGE-BSA (100 nM for 48 h), organized actin structures were almost com-
pletely disrupted, remants of circumferential and central stress fiber arrays, repre-
sented by actinaggregates, were scattered throughout thecytoplasm (Fig. 7 C). Con-
comitant with these advanced changes in the actin-based cytoskeleton, retraction
of cellular margins resulted in formation of intercellular gaps between contiguous
cells. These gaps provide a paracellular pathway forescape of intravascular contents
into the vessel wall.
Modulation ofEndothelial Cell Coagulant Properties by AGE-BSA.
￿
Alterations in vas-
cularpermeability are closely linked to perturbation ofthecoagulation mechanism,
since access ofplasma proteins to subendothelium, such as would result from retrac-
tion of endothelial cells, upregulates the procoagulant response. Conversely, activa-
tion of coagulation on the endothelial surface leads to the formation of proteases
and fibrin that can alter endothelial cell shape and increase vascular permeability1398
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(16, 27) . These considerations led us toexamine ifexposure of endothelium to AGE-
BSA could alter certain cell surface anti- and procoagulant properties .
Since the central anticoagulant protein C/protein S pathway is closely linked to
endothelium, webegan ourstudiesby examiningmodulation ofthromobomodulin
by AGE-BSA. Thrombomodulin is an endothelial cell surface cofactor promoting
thrombin-mediated formation ofthe anticoagulant enzyme activated proteinC (17) .
Incubation of endothelial cultures with AGE-BSA at 37°C led to a time-dependent
decline in cell surface thrombomodulin activity (Fig. 8 A) . Suppression of throm-
bomodulin activity was evident by 1 h, reached amaximum by 20 h, and persisted
up to the longesttime points tested (48h) . AGE-BSA-induced suppression ofthrom-
bomodulin activity was also dependent on the dose ofAGE protein added, being
half-maximal at -70-100nM (Fig. 8B) . In contrast, prolonged incubations or high
concentrations of native BSA did not depress thrombomodulin activity (Fig . 8, A
andB) . This indicates that the effect ofAGE-BSAon this cellular anticoagulant prop-
ertywasdueto theAGE form ofthe protein and paralleled occupancy of cell surface
binding sites (Fig . 3 C), suggesting that the cell-bound ligand is mediating the cel-
lular effect .
In contrast to the fall in thrombomodulin activity on the cell surface, total cellular
thrombomodulin antigen was not suppressed (Fig. 8 C), suggesting that redistribu-
tion, possibly making it inaccessible to thrombin, rather than degradation or shed-
ding, hadoccurred . Visualizationofthrombomodulin by immunofluorescence during
the incubation withAGE-BSA(under conditions inwhich the antithrombomodulin
antibodywas incubated with nonpermeabilized cells so that only cell surface ligand
FIGURE 8.
￿
Effect ofAGE-BSA on endothelial thrombomodulin . (A) Time course. Cultureswere
incubated with AGE-BSA (200 nM) (open circles) or medium supplemented with normal BSA
(200 nM) (closed circles) at 37°C for the indicated times and then thrombomodulin activity was
determined by assessing thrombin-mediated activation ofproteinC . (B) Dose response. Cultures
were incubatedwith the indicated concentrations ofAGE-BSA (open circles) or normalBSA (closed
circles) and after 5 h at 37°C, thrombomodulin activity was assessed . Data inA-Bare expressed
as percent maximal thrombomodulin activity. (C) RIA for thrombomodulin antigen. Cultures
were incubated in medium supplemented with normal BSA (250 nM ; Co) or AGE-BSA (250
nM ; AGE-BSA) for 24 h . Monolayers were then solubilized with NP-40 in the presence ofinhibi-
tors and thrombomodulin antigen was assessed by radioimmunoassay. Thrombomodulin antigen
per 106 cells, the mean t SD, is shown in each case, and details of experimental methods are
described in the text .1400
￿
ENDOTHELIUM AND GLUCOSE-MODIFIED PROTEINS
FIGURE 9.
￿
Immunofluorescence studyofthrombomodulin : effect ofAGE-BSA. Endothelial cell
monolayers were incubated in normal medium (A) or medium supplemented with AGE-BSA
(100nM) (B) for 48 h and thrombomodulin was visualized by immunofluorescence as described
in the text . The micrograph ofthe treated cultures inBdemonstrates reduced fluorescence inten-
sity compared with the untreated controls in A . Bar, 10 /Am .
was accessible), demonstrated a decrease in fluorescence intensity (Fig . 9) . No evi-
dence of increased thrombomodulin shedding was detectable by immunofluores-
cence or RIA of supernatants from AGE-BSA-treated endothelial cultures . Further-
more, AGE-BSA did not have a direct effect on thrombomodulin activity when
experiments were performed with purified thrombomodulin . Thesedata suggest that
sequestration ofthrombomodulin at an inaccessible site, with respect to enzyme and
substrate present in theextracellular compartment, may be the predominant mech-
anism of AGE-BSA-mediated downregulation of this cell surface anticoagulant .
Although LPShas been reported to downregulate endothelial cell thrombomodulin
(34), polymyxin B (which was present in the incubation buffer for studies of en-
dothelial coagulant function) had no effect on AGE-BSA-mediated suppression of
thrombomodulin and heat-treated AGE-BSA was inactive (data not shown) . Fur-
thermore, as described above, no LPS was detectable in theAGE-BSA preparations
used .
In parallel with suppression ofthe cell surface activity ofthe anticoagulant cofactor
thrombomodulin, exposure ofendothelium to AGE-BSA led to an increase in en-
dothelial cell procoagulant activity, which was tissue factor, based on its inhibition
in the presence ofaneutralizing monoclonal antibody (Fig . 10). Induction of tissue
factor occurred steadily over several days and could be inhibited in the presence of
cycloheximide, indicating the importance of de novo protein synthesis for expres-
sion ofthis procoagulant activity (Fig . 10 A) . Theeffect ofAGE-BSA on tissue factor
was also dependent on the dose ofAGE-BSA added, being half-maximal at ti 100-150
nM (Fig. 10 B) . As with AGE-BSA-mediated suppression of thrombomodulin, heat-
treated AGE-BSA was ineffective and polymyxinB (the latter was added to culture
medium in all experiments examining endothelial tissue factor expression) had noESPOSITO ET AL .
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FIGURE 10 . Effect of AGE-
BSA on endothelial cell tissue
factor activity . (A) Time course .
Endothelial monolayers werein-
cubated for the indicated times
in medium supplemented with
AGE-BSA (220 nM). Where
indicated, cycloheximide was
added to cultures simultane-
ously with AGE-BSA (x). Tis-
sue factor activity was then as-
sessed as described in the text .
(B) Dose response . Endothelial
cell monolayers were incubated
for 48 h in medium supplemented with the indicated amount ofAGE-BSA and tissue factor activity
was assessed . (C) Effect ofTNF on AGE-BSA-induced tissue factor activity. Endothelial cell monolayers
were incubated with normal medium or medium supplemented with AGE-BSA (55 nM) . Then the
incubation period was continued for 6 h using either the same medium or medium supplemented with
TNF (0.03 nM). Where indicated, AGE-BSA was replaced by heat-treated AGE-BSA (0 .5 wM) (heat) .
Tissue factor activity ofmonolayers was then assessed . Details ofexperimental procedure are described
in the text . The average of duplicate determinations is shown . 0, cultures incubated in normal medium
alone; AGE-BSA, cultures incubated in medium supplemented withAGE-BSA ; TNF, cultures incubated
in normal medium for 48 h followed by a 6-h incubation with TNF; AGE-BSA + TNF, cultures in-
cubated with medium supplemented with AGE-BSA for 48 h followed by a 6-h incubation withTNF.
Data shown are the means t SD.
effect . Furthermore, native BSA had no effect on endothelial tissue factor activity.
Taken together, thesedata indicate that AGE-BSA boundto its specific binding sites
was the active species for induction of tissue factor in these studies .
In view of the sustained induction oflow amounts of tissue factor in endothelium
by AGE-BSA, we examined whether AGE-BSA could prime the cells to respond
to a challenge with TNF, an agent that results in the induction of greater amounts
of tissue factor activity, but within hours (5, 38) . Addition of TNF (0.03 nM) to
cultures incubated with AGE-BSA (55 nM) gave enhanced induction ofprocoagulant
activity compared with either agent alone (Fig . 10 C) . Experiments carried out with
endothelial cultures preincubated for 3 d with AGE-BSA and then exposed to sev-
eral low concentrations of TNF (0.05-0.2 nM) also demonstrated increased tissue
factor induction, compared with that observed when either agent was present alone.
Discussion
The results of this study indicate that endothelium expresses a binding site that
selectively interacts with glucose-modified BSA(AGE-BSA), andprobably otherAGE-
modified proteins as well, in a manner distinct from normal albumin (32, 42, 43) .
Albumin, which has ahalf-life in the circulation of-19 d, hasdetectableAGEs within
3 d of exposure to high glucose concentrations (12) and has sufficient AGEs within
16 d to interact with the endothelial cell binding site (Fig . 4) . It is therefore likely
that small amounts of circulating glucose-modified (AGE) plasma proteins (such
as Igs, albumin, and lipoproteins) are bound by the vascular endothelium in vivo .
The presence of these binding sites or putative receptors forAGE adducts of pro-
teins on the vessel surface suggests that their interaction with endothelium could
result in clearance from the intravascular space and/or modulation of vascular func-
tion . Consistent with this concept, cell surface binding of radiolabeled AGE-BSA1402
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is followed by endocytosis with subsequent degradation and/or transcytosis. Oflarger
in vivo significance, however, may be the interaction of endothelial AGE-binding
siteswith subendothelial AGEproteins in the matrix, whichaccumulate dueto their
slow turnover rate (8, 10, 11, 33). Although endotheliummay play arole in the clear-
ance of theseAGEs, ourdata indicate that occupancyofthe endothelial AGE binding
site results in perturbation ofendothelial barrier andcoagulantfunction, potentially
contributing to the pathogenesis of diabetic microvascular hyperpermeability and
hypercoagulability.
The binding of AGE-BSA to endothelium reported here shares several features
in common with that previously reported for the interaction of 1251-AGE-BSA with
macrophages (52). In both cases a limited number of binding sites specific for the
AGE moiety of the protein were present with a Kd of -70-100 nM. Structurally,
it is possible that different binding sites exist on macrophages and endothelial cells
that recognize only some ofthelarge family of AGE adducts. For example, thechem-
ically defined AGE adduct FFI (39) is notrecognized by theendothelial AGE-binding
site, although it binds to themacrophage with comparable affinity to AGE-BSAand
can elicit functional alterations, such as cytokine elaboration (54).
Exposure of endothelial cultures to AGE-BSA resulted in alterations in cell
shape/cytoskeleton alongwith peturbation ofbarrierand coagulant function. In con-
trast to the effect of TNF on endothelial permeability, which was maximal within
several hours (7), AGE-BSA-induced perturbation of endothelial permeability re-
quired several days. Increased permeability to [3H]inulin occurred concomitantly
with AGE-BSA-induced formation of intercellular gaps in the monolayer, presum-
ably dueto this paracellular pathway. Enhanced vascular permeability could increase
access ofplasma proteins from the intravascular space to the subendothelium, poten-
tially providing a basis for the accumulation of protein in the vessel wall, such as
hasbeen observed in diabetic and agingvasculature(8, 10, 11, 33). In addition, after
binding to the cell surface, AGE-BSA was apparently transcytosed and deposited
within hours on the endothelial-derived extracellular matrix. Thus, transcytosis of
AGE-BSA was probably also contributing to the permeability defect. The presence
of these mechanisms delivering AGEs to the basement membrane could explain,
at least in part, theirdeposition in this locus in vivo and their potential contribution
as long-term regulators of endothelial function by altering the composition of the
extracellular matrix.
Although our findings with AGE-BSA and cultured bovine aortic endothelium
and those recently reported by Predescu et al. (40) with glycoalbumin and native
murine coronary endothelium are in general agreement, there are multiple differ-
ences, as well. Predescu et al. demonstrated binding of gold-labeled glycoalbumin
to endothelium that was partially inhibitable by native albumin and glucose, and
almost completely blocked by the combination of these two. In contrast, our data
indicate that neither of these agents affected AGE-BSA binding to the surface of
cultured endothelial cells. There are several possible explanations for these differ-
ences. On the one hand, the source of endothelium in the two studies was quite
different, i.e., cultured large vessel bovine endothelium and native microvascular
endothelium. More importantly, the glycoalbumin used by Predescu et al. was pre-
paredby incubating albumin with glucose (at90 mM) for 14 d, andwas distinguished
from nonglycosylated albumin by the presence of an abundance of early glycosyla-
tion products (Amadori; reference 11). We have previously found that detectableESPOSITO ET AL.
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amounts ofAGE form under these conditions (9), thus accounting for the competi-
tive inhibition shown at 16 d using ourpreparations (Fig. 4). However, our glycosylated
albumin preparations have been shown to be maximally modified by AGE after6 wk
of incubation with glucose (unpublished observation). Future studies of thebinding
of AGE-BSA and other forms of glycosylated albumin to the vessel surface in vivo,
andto different typesofendothelium in vitro, will be required to resolve these questions.
In addition to increasing permeability of the endothelial monolayer to intravas-
cular solutes, AGE-BSA modulated endothelial coagulant function, potentially
promoting activation of the clotting mechanism on the vessel surface; expression
of thrombomodulin was suppressed and induction of tissue factor was enhanced.
The effects of AGE-BSA on these endothelial coagulant properties were slower in
their onset and more sustained, compared with the more rapid effects of cytokines
such as TNF (4, 7, 14, 19, 35, 38). Furthermore, in contrast to TNF, whichdecreases
total thrombomodulin antigen in parallel with the fall in cell surface thrombomodulin
activity (14, 19, 35), AGE-BSA did not depress the pool of total thrombomodulin
antigen, but rather exerted its effect more selectively on accessibility of the cell sur-
face receptor. Inductionoftissue factor in response to AGE-BSAwas also quitedifferent
than the response to cytokines, such as TNF or IL-1 (4, 7, 38, 45). At least 2-3 d
were required for induction of maximal tissue factor activity with AGE-BSA and
that activity was maintained forseveral days when AGE-BSA was allowedto remain
in the culture medium. In contrast, the cytokines induce maximal tissue factor ac-
tivity by -6 h, which subsequently decays to the baseline by 24 h, even when present
at lower concentrations (7, 38, 45). These findings, taken together with the results
described above, support ourconclusion that theeffects ofAGE-BSAon endothelium
are mediated, at leastinitially, by mechanisms involvingAGE-BSA interaction directly
with its cell surface receptor. The possible role of AGE-mediated induction of en-
dothelial cytokine elaboration in explaining longer-term effects of these modified
proteins on endothelium remains to be examined. In this context, in pilot studies
we were unable to demonstrate induction of IL-1 synthesis during exposure of en-
dothelial cultures to AGE-BSA.
Thesestudiesrepresentan initialcharacterization oftheinteraction ofAGE-proteins,
with AGE-BSA as a prototype, with endothelium. Many important issues remain
to be examined, such as comparison of the endothelial cell receptor (ofmicro- and
macrovascular-derived cells) with its counterpart recently describedon macrophages,
the ability of the receptor to interact with a spectrum ofAGE-proteins, and the full
range of cellular properties modulated by AGE-BSA endothelial interaction. Since
AGE-proteins accumulate in the basement membrane, modulation of endothelial
cell function by an abnormal extracellular matrix must be examined. In this con-
text, preliminary studies indicate that modulation of coagulant properties can occur
with endothelial cells seeded on AGE matrix. Although the in vivo physiologic rele-
vance of these findings in cell culture is not yet clear, they may provide a basis for
the initiation of early vascular pathology as manifested by increased permeability,
as well as widespread coagulopathy.
Summary
Advanced glycosylation end products (AGE) of proteins accumulate in the vas-
culature with diabetes and aging, and are thought to be associated with vascular1404
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complications. This led us to examine the interaction of AGE-BSA as a prototype
ofthis class ofnonenzymatically glycosylated proteins subjected to further processing,
with endothelium. Incubation of "'I-AGE-BSA with cultured bovine endothelium
resulted in time-dependent, saturable binding that was half-maximal at a concen-
tration of -100 nM. Although unlabeled normal BSA was not a competitor, unla-
beled AGE-BSA was an effective competitor of 125I-AGE-BSA-endothelial cell in-
teraction. In addition, AGE modification of two alternative proteins, hemoglobin
and ribonuclease, rendered them inhibitors of "5I-AGE-BSA binding to endothe-
lium, although the native, unmodified forms of these proteins were not. At 37 °C,
binding of "'I-AGE-BSA or gold-labeled AGE-BSA was followed by internaliza-
tion and subsequent segregation either to a lysosomal compartment or to the
endothelial-derived matrix after transcytosis. Exposure ofendothelium to AGE-BSA
led to perturbation of two important endothelial cell homeostatic properties, coagu-
lant and barrier function. AGE-BSA downregulated the anticoagulant endothelial
cofactor thrombomodulin, and induced synthesis and cell surface expression of the
procoagulant cofactor tissue factor over the same range ofconcentrations that resulted
in occupancy ofcell surface AGE-BSA binding sites. In addition, AGE-BSA increased
endothelial permeability, resulting in accelerated passage of an inert macromolecular
tracer, [3H]inulin, across the monolayer. These results indicate that AGE deriva-
tives of proteins, potentially important constituents of pathologic vascular tissue,
bind to specific sites on the endothelial cell surface and modulate central endothelial
cell functions. The interaction ofAGE-modified proteins with endothelium may play
an important role in the early stages of increased vascular permeability, as well as
vessel wall-related abnormalities of the coagulation system, characteristic ofdiabetes
and aging.
Dr. Godman (Department of Pathology, Columbia University) provided invaluable sugges-
tions and critique of this manuscript. We thank Sam Rover for his generous contribution.
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